Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Research scientist at the Public Research Organisation (PRO) at the Institute of Biomedicine of Valencia of the Spanish National Research Council (CSIC) and principal investigator at CIBERNED
A review of studies conducted by the Cochrane Collaboration analyzed data from 17 clinical trials involving more than 20,000 participants who had been treated with amyloid-targeting drugs—such as lecanemab or donanemab—at a relatively early stage of Alzheimer’s disease. Results at 18 months of treatment show that “the absolute effects on cognitive decline and the severity of dementia were nonexistent or negligible, falling well below the thresholds established for a clinically meaningful difference,” according to a press release. Furthermore, the review concludes that these drugs likely cause more brain inflammation and microbleeds than the placebo.
A clinical trial (COSMOS) involving 958 healthy adults with an average age of 70 tested the ability of a multivitamin supplement, together with cocoa extract, to slow ageing. The results, published in Nature Medicine, show that the supplement slightly slowed two of the five biological markers of ageing measured after two years of daily use. The two markers affected were PCPhenoAge and PCGrimAge, whose rate of increase was reduced by 2.6 months and 1.4 months respectively. The slowing effect was greater among participants who initially showed more accelerated ageing. Cocoa showed no effect.